Recent

% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

  • hardluckchuck2002 hardluckchuck2002 Sep 15, 2012 10:53 AM Flag

    BioCryst Pharmaceuticals Inc Files Patent Application for Pyrrolo [1, 2-B] Pyridazine Derivatives as Janus Kinase Inhibitors

    New Delhi, Sept. 15 -- USA based BioCryst Pharmaceuticals Inc filed patent application for pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors. The inventors are Babu Yarlagadda S, Kotian Pravin L, Kumar V Satish, Wu Minwan and Lin Tsu-Hsing.

    BioCryst Pharmaceuticals Inc filed the patent application on Feb. 6, 2012. The patent application number is 291/MUMNP/2012 A. The international classification number is C07D 487/04.

    According to the Controller General of Patents, Designs & Trade Marks, "The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Does anybody know what this is about? The last sentence "... and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I" is intriguing.

      From wikipedia: "Janus kinase inhibitor is a class of medicines that function by inhibiting the effect of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), interfering with the JAK-STAT signaling pathway.
      Some JAK2 inhibitors are under development for the treatment of polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.[1] Some inhibitors of JAK2 are in clinical trials, e.g. for psoriasis.[2]
      JAK3 is also being targeted for a variety of inflammatory diseases, and one has had good results in a phase II trial for rheumatoid arthritis.[3]

      PS: Thanks for posting Hardluck.

    • Hey JACKO, NO ONE CARES. Does this help the company SELL ANYTHING, make money or stop their CASH BURN to BK? Well, there ya go.

      Sentiment: Strong Sell

 
BCRX
15.48+0.14(+0.91%)Jul 31 4:00 PMEDT